Crystal Structure of Apo MEF2B Reveals New Insights in DNA Binding and Cofactor Interaction.

The myocyte enhancer factor 2 (MEF2) family of transcription factors plays important roles in developmental processes and adaptive responses. Although MEF2 proteins are known to bind DNA in the nucleus to regulate specific gene expression, there are reports that show that MEF2 also functions in the cytoplasm. Previous structural studies of MEF2 focused exclusively on DNA-bound MEF2 with and without various corepressors or coactivators. While these studies have established a comprehensive structural model of DNA recognition and cofactor recruitment by MEF2, the structure of MEF2 not bound to DNA, which include cytoplasmic MEF2 and free MEF2 in the nucleus, is unknown. Here we determined the structure of the MADS-box/MEF2 domain of MEF2B without DNA nor cofactor. The Apo structure of MEF2B reveals a largely preformed DNA binding interface that may be important for recognizing the shape of DNA from the minor groove side. In addition, our structure also reveals that the C-terminal helix of the MEF2-specific domain could flip up to bind to the hydrophobic groove that serves as the binding sites of MEF2 transcription cofactors. These observations shed new insights into DNA binding and cofactor interaction by MEF2 proteins.

[1]  Jared M. Sagendorf,et al.  Expanding the repertoire of DNA shape features for genome-scale studies of transcription factor binding , 2017, Nucleic acids research.

[2]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[3]  S. Ferrari,et al.  Inhibition of myogenesis by transforming growth factor beta is density-dependent and related to the translocation of transcription factor MEF2 to the cytoplasm. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  K. Franchini,et al.  FAK Forms a Complex with MEF2 to Couple Biomechanical Signaling to Transcription in Cardiomyocytes. , 2016, Structure.

[5]  Shannon N. Tessier,et al.  Expression of myocyte enhancer factor-2 and downstream genes in ground squirrel skeletal muscle during hibernation , 2010, Molecular and Cellular Biochemistry.

[6]  Le Li,et al.  MADS-Box Transcription Factor SsMADS Is Involved in Regulating Growth and Virulence in Sclerotinia sclerotiorum , 2014, International journal of molecular sciences.

[7]  S. Masiero,et al.  INCOMPOSITA: a MADS-box gene controlling prophyll development and floral meristem identity in Antirrhinum , 2004, Development.

[8]  Lin Yang,et al.  DNA Shape Features Improve Transcription Factor Binding Site Predictions In Vivo. , 2016, Cell systems.

[9]  E. Olson,et al.  Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Basso,et al.  MEF2B mutations lead to deregulated expression of the BCL6 oncogene in Diffuse Large B cell Lymphoma , 2013, Nature Immunology.

[11]  G. Muscat,et al.  Subcellular localization of the steroid receptor coactivators (SRCs) and MEF2 in muscle and rhabdomyosarcoma cells. , 2001, Molecular endocrinology.

[12]  Lin Chen,et al.  Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2 , 2003, Nature.

[13]  Eric S. Lander,et al.  Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.

[14]  R. Treisman,et al.  Human SRF-related proteins: DNA-binding properties and potential regulatory targets. , 1991, Genes & development.

[15]  M. Marra,et al.  MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation , 2015, Nature Communications.

[16]  Hua Li,et al.  The MADS-Box transcription factor Bcmads1 is required for growth, sclerotia production and pathogenicity of Botrytis cinerea , 2016, Scientific Reports.

[17]  S. de Folter,et al.  Conservation and evolution in and among SRF- and MEF2-type MADS domains and their binding sites. , 2011, Molecular biology and evolution.

[18]  A. Deutch,et al.  Localization of myocyte enhancer factor 2 in the rodent forebrain: Regionally-specific cytoplasmic expression of MEF2A , 2009, Brain Research.

[19]  Jun O. Liu,et al.  Mechanism of recruitment of class II histone deacetylases by myocyte enhancer factor-2. , 2004, Journal of molecular biology.

[20]  M. Marra,et al.  MEF2 transcription factors: developmental regulators and emerging cancer genes , 2015, Oncotarget.

[21]  R. Mann,et al.  The role of DNA shape in protein-DNA recognition , 2009, Nature.

[22]  N. Jayathilaka,et al.  Structure of the MADS-box/MEF2 domain of MEF2A bound to DNA and its implication for myocardin recruitment. , 2010, Journal of molecular biology.

[23]  E. Olson,et al.  MEF2: a central regulator of diverse developmental programs , 2007, Development.

[24]  T. Richmond,et al.  Crystal structure of MEF2A core bound to DNA at 1.5 A resolution. , 2000, Journal of molecular biology.

[25]  Ryan D. Morin,et al.  Theoretical Investigation of the D83V Mutation within the Myocyte-Specific Enhancer Factor-2 Beta and Its Role in Cancer , 2013 .

[26]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[27]  Yang Fu,et al.  The Cancer Mutation D83V Induces an α-Helix to β-Strand Conformation Switch in MEF2B. , 2018, Journal of molecular biology.

[28]  I. Varela,et al.  Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. , 2017, The Journal of investigative dermatology.

[29]  Jun O. Liu,et al.  Structure of p300 bound to MEF2 on DNA reveals a mechanism of enhanceosome assembly , 2011, Nucleic acids research.

[30]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[31]  G M Clore,et al.  Solution structure of the MEF2A–DNA complex: structural basis for the modulation of DNA bending and specificity by MADS‐box transcription factors , 2000, The EMBO journal.